Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, Parkinson's disease, multiple sclerosis, spinal cord injury, type-2 diabetes, melanoma and breast cancers, among others.